Skip to main content

Avalo Therapeutics, Inc.

corporate_fare Company Profile

Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed AVTX - Latest Insights

AVTX
Apr 28, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
8
AVTX
Apr 28, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
AVTX
Apr 23, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
AVTX
Apr 10, 2026, 4:01 PM EDT
Filing Type: DEF 14A
Importance Score:
7
AVTX
Mar 27, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
AVTX
Mar 23, 2026, 7:02 AM EDT
Filing Type: 10-K
Importance Score:
8
AVTX
Mar 23, 2026, 7:01 AM EDT
Filing Type: 8-K
Importance Score:
7
AVTX
Mar 16, 2026, 4:39 PM EDT
Filing Type: 144
Importance Score:
7
AVTX
Jan 12, 2026, 7:53 AM EST
Filing Type: 8-K
Importance Score:
8
AVTX
Jan 08, 2026, 4:01 PM EST
Filing Type: S-3
Importance Score:
8